Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

In cancer-associated cachexia, elevated TNF-α and IL-6 exacerbate muscle and fat loss by regulating multiple metabolic signaling pathways, which could be ameliorated by Z526's suppression of NF-κB ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...

Researchers have discovered how a particular protein affects the growth and spread of colon cancer in humans. The study not ...

In a nutshell Researchers discovered how a specific genetic mutation (PIK3CA) changes the way blood vessel cancers grow and ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

In a report released today, Roger Song from Jefferies maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target of ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These ...